WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001022970) THERAPY WITH 2-5A AND INTERFERON
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/022970    International Application No.:    PCT/US2000/041038
Publication Date: 05.04.2001 International Filing Date: 29.09.2000
Chapter 2 Demand Filed:    27.04.2001    
IPC:
A61K 38/21 (2006.01), A61K 45/06 (2006.01)
Applicants: THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Avenue, Cleveland, OH 44195 (US) (For All Designated States Except US).
SILVERMAN, Robert, H. [US/US]; (US) (For US Only).
RUSCH, Lorraine [US/US]; (US) (For US Only)
Inventors: SILVERMAN, Robert, H.; (US).
RUSCH, Lorraine; (US)
Agent: DOCHERTY, Pamela, A.; Calfee, Halter & Griswold LLP, Suite 1400, 800 Superior Avenue, Cleveland, OH 44114 (US)
Priority Data:
60/156,542 29.09.1999 US
Title (EN) THERAPY WITH 2-5A AND INTERFERON
(FR) THERAPIE A BASE DE 2-5A ET D'INTERFERON
Abstract: front page image
(EN)New methods of treating malignancies in a subject are provided. Such methods comprise administering 2', 5' oligoadenylate (2-5A) or a biostable analog of 2-5A to the subject. In some embodiments, IFN is also administered to the subject. Examples of cancers which may be treated according to the present method include, but are not limited to, hairy cell leukemia, Kaposi's sarcoma, CML, B-cell and T-cell lymphomas, melanomas, myelomas, renal cell carcinoma, ovarian, breast, bronchogenic, bladder, and gastrointestinal carcinomas and acute leukemias, malignant glioma and fibrosarcoma. Methods of treating viral diseases in a subject are also provided. Such methods comprise administering interferon and 2', 5' oligoadenylate (2-5A) or a biostable analog of to a subject. Examples of viral diseases which may be treated according to this method include, but are not limited to, hepatitis C, hepatitis B, and viral infections caused by human papilloma virus or a picornavirus. A method of selectively inducing programmed cell death (apoptosis) in cancer cells either in vitro or in vivo is also provided. The method comprises administering 2-5A or a biostable analog thereof to the cancer cells.
(FR)L'invention concerne des procédés relatifs au traitement de tumeurs malignes, qui consistent à administrer du 2', 5' oligoadénylate (2-5A) ou un analogue biostable de 2-5A au patient. Eventuellement, on administre également de l'interféron (IFN). Il est possible de traiter par exemple les cancers suivants (liste non exhaustive) : leucémie à cellules 'chevelues', sarcome de Kaposi, leucémie myéloïde chronique, lymphomes B et T, mélanomes, myélomes, hypernéphromes, cancer des ovaires, du sein, des bronches,de la vessie, carcinomes gastrointestinaux, leucémie aiguë, gliomes malins et fibrosarcomes. L'invention concerne également des procédés relatifs au traitement de maladies virales, qui consistent à administrer à la fois de l'IFN et du 2', 5' oligoadénylate (2-5A) ou un analogue biostable de 2-5A au patient. Il est possible de traiter par exemple les maladies virales suivantes (liste non exhaustive) : hépatite C, hépatite B, et infections virales induites par un papillomavirus ou un picornavirus humain. L'invention concerne en outre un procédé permettant d'induire de manière sélective la mort cellulaire programmée (apoptose) dans les cellules cancéreuses, in vitro ou in vivo, en administrant à ces cellules du 2-5A ou un analogue biostable.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)